Atopic Dermatitis and Ulcerative Colitis Successfully Treated with Upadacitinib
, Martina Caviglia 1, Giuseppina Cusano 2, Alvise Sernicola 1,*, Camilla Chello 1, Ester Del Duca 1, Carmen Cantisani 1, Alberto Taliano 1, Nicolò Sini 1, Gianluca Ianiro 3 and Giovanni Pellacani 1Round 1
Reviewer 1 Report
It is an interesting case report.
Authors report the case of a 36-year-old male patient presenting an overlap of ulcerative colitis, a Th1 related disease, and atopic dermatitis, a Th2 mediated condition. Treatment with upadacitinib was initiated, laboratory and instrumental follow-up was carried out for 8 months. Results: Complete and persistent clinical remission of both conditions was observed at a low dose of upadacitinib 15 mg, despite ulcerative colitis guidelines usually recommend a dosage of 45 mg. No serious adverse events to therapy were reported. Conclusions: Upadacitinib may be the most suitable management strategy in subjects with coexisting severe conditions mediated by Th1 inflammation, such as ulcerative colitis, and by Th2 cytokines, such as atopic dermatitis.
Author Response
Reviewer 1
It is an interesting case report.
Authors report the case of a 36-year-old male patient presenting an overlap of ulcerative colitis, a Th1 related disease, and atopic dermatitis, a Th2 mediated condition. Treatment with upadacitinib was initiated, laboratory and instrumental follow-up was carried out for 8 months. Results: Complete and persistent clinical remission of both conditions was observed at a low dose of upadacitinib 15 mg, despite ulcerative colitis guidelines usually recommend a dosage of 45 mg. No serious adverse events to therapy were reported. Conclusions: Upadacitinib may be the most suitable management strategy in subjects with coexisting severe conditions mediated by Th1 inflammation, such as ulcerative colitis, and by Th2 cytokines, such as atopic dermatitis.
Dear Reviewer 1,
Thank you for your careful review of our paper.
Reviewer 2 Report
The work reported upadacitinib could be used as an appropriate management strategy in subjects with severe co-existing cytokine-mediated conditions TH1 and Th2. It might be useful for some readers.
Author Response
Reviewer 2
The work reported upadacitinib could be used as an appropriate management strategy in subjects with severe co-existing cytokine-mediated conditions TH1 and Th2. It might be useful for some readers.
Dear Reviewer 2,
Thank you for your efforts on our paper and for the encouraging comments.
